Loratadine

Summary

Loratadine (CHEMBL998) is an approved small-molecule H1-receptor antagonist (ATC R06AX13) targeting HRH1, TRPV2, and SLC6A15; indicated across 17 conditions including seasonal allergic rhinitis and allergic rhinitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AX13
• Targets: 3 (HRH1, TRPV2, SLC6A15)
• Indications: 17 conditions
• Clinical trials: 58
• Chemistry: 382.9 Da · C22H23ClN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL998
Name	Loratadine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3957
ChEBI	CHEBI:6538
ATC	R06AX13
Molecular formula	C22H23ClN2O2
Molecular weight	382.9
InChIKey	JCCNYMKQOSZNPW-UHFFFAOYSA-N

SMILES: CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1

IUPAC name: ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate

ChEBI definition: A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.

Pharmacological roles (ChEBI): geroprotector, H1-receptor antagonist, anti-allergic agent, cholinergic antagonist.

Also known as: Alavert, Children’s claritin, Claritin, Claritin hives relief, Claritin hives relief reditab, Claritin reditabs, Clarityn, Clarityn rapide, Clarityne, Hay-rite, Loratadina, Loratadine

Parent form; salt/anhydrous children: CHEMBL4092143

Patent coverage: 13,256 distinct patent families (42,161 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 41,967 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HRH1	H1 receptor	Antagonist	7.43	0%	P35367
TRPV2	TRPV2	Inhibition	5.52	1.4%	Q9Y5S1
SLC6A15	B0AT2	Inhibition	5.4	0.1%	Q9H2J7

Broader ChEMBL bioactivity targets: 49 (assay-derived). Sample: Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, RecQ-like DNA helicase BLM, Inositol monophosphatase 1, Thrombopoietin, NPC intracellular cholesterol transporter 1, Geminin, Ras-related protein Rab-9A, Peripheral myelin protein 22, 5-hydroxytryptamine receptor 2B, Histamine H2 receptor, Thyrotropin receptor, Bile acid receptor, Thromboxane A2 receptor, Menin/Histone-lysine N-methyltransferase MLL, Voltage-gated L-type calcium channel, Muscarinic acetylcholine receptor M2.

Bioactivity

ChEMBL activities: 46 potent at pChembl ≥ 5 of 99 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	7.8	IC50	16	nM	CHEMBL_ACT_7776682
HRH1	7.7	Ki	20	nM	CHEMBL_ACT_7776727
HRH1	7.43	Ki	37	nM	CHEMBL_ACT_1404989
CYP2C9	7.4	Potency	39.8	nM	CHEMBL_ACT_5033539
P31389	7.14	Kd	72.44	nM	CHEMBL_ACT_15176659
HTR2B	6.81	Ki	156	nM	CHEMBL_ACT_7778820
KCNH2	6.77	IC50	169.8	nM	CHEMBL_ACT_1029992
KCNH2	6.77	IC50	169.8	nM	CHEMBL_ACT_1523668
KCNH2	6.77	IC50	169.8	nM	CHEMBL_ACT_2358297
HRH1	6.77	IC50	170	nM	CHEMBL_ACT_7776726
KCNH2	6.76	IC50	173.8	nM	CHEMBL_ACT_2645521
KCNH2	6.76	IC50	173	nM	CHEMBL_ACT_307855
KCNH2	6.76	IC50	173.8	nM	CHEMBL_ACT_5219042
HRH1	6.72	Kd	190	nM	CHEMBL_ACT_20714586
HTR2B	6.61	IC50	245	nM	CHEMBL_ACT_7778819
HRH1	6.54	IC50	290	nM	CHEMBL_ACT_1618290
HRH1	6.51	Ki	311	nM	CHEMBL_ACT_15135330
P31390	6.46	Ki	350	nM	CHEMBL_ACT_500732
CYP2C19	6.4	Potency	398.1	nM	CHEMBL_ACT_4006378
HRH1	6.38	Ki	414	nM	CHEMBL_ACT_1455412
P97697	6.35	Potency	446.7	nM	CHEMBL_ACT_4411678
HRH2	6.16	AC50	696.4	nM	CHEMBL_ACT_25114337
OPRK1	6.02	AC50	963.9	nM	CHEMBL_ACT_25129027
HTR2B	5.91	AC50	1234	nM	CHEMBL_ACT_25163993
P08482	5.9	Potency	1259	nM	CHEMBL_ACT_4799535
HRH1	5.75	AC50	1800	nM	CHEMBL_ACT_25212060
CYP2C19	5.55	IC50	2800	nM	CHEMBL_ACT_15445901
CYP2C8	5.53	IC50	2950	nM	CHEMBL_ACT_15447383
NR1I2	5.52	EC50	3000	nM	CHEMBL_ACT_13362891
NR1H4	5.51	IC50	3070	nM	CHEMBL_ACT_13348764
MEN1	5.45	Potency	3548	nM	CHEMBL_ACT_4574099
SLC6A15	5.4	IC50	4000	nM	CHEMBL_ACT_15135367
NPSR1	5.4	Potency	3981	nM	CHEMBL_ACT_4941249
HTR2A	5.23	AC50	5849	nM	CHEMBL_ACT_25173461
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_4977444
CYP3A4	5.2	Potency	6310	nM	CHEMBL_ACT_5042642
SLC6A3	5.18	AC50	6540	nM	CHEMBL_ACT_25123507
NPSR1	5.1	Potency	7943	nM	CHEMBL_ACT_4901438
ADORA3	5.09	AC50	8120	nM	CHEMBL_ACT_25133766
OPRM1	5.09	AC50	8200	nM	CHEMBL_ACT_25157149
CHRM2	5.09	AC50	8055	nM	CHEMBL_ACT_25195153
ADRB3	5.07	AC50	8500	nM	CHEMBL_ACT_25153196
NR1I2	5	EC50	10000	nM	CHEMBL_ACT_15463755
NR1I2	5	EC50	10000	nM	CHEMBL_ACT_15465494
MAPT	5	Potency	10000	nM	CHEMBL_ACT_4055023
MEN1	5	Potency	10000	nM	CHEMBL_ACT_4581682

Target pathways

Aggregated over 3 target gene(s): HRH1, TRPV2, SLC6A15.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	1	TRPV2
Amino acid transport across the plasma membrane	1	SLC6A15
Transport of small molecules	1	SLC6A15
Histamine receptors	1	HRH1
G alpha (q) signalling events	1	HRH1
R-HSA-425366	1	SLC6A15
R-HSA-425393	1	SLC6A15
SLC-mediated transmembrane transport	1	SLC6A15
SLC-mediated transport of neurotransmitters	1	SLC6A15

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	2
transmembrane transport	2
inflammatory response	1
G protein-coupled receptor signaling pathway	1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
chemical synaptic transmission	1
memory	1
visual learning	1
regulation of vascular permeability	1
positive regulation of vasoconstriction	1
regulation of synaptic plasticity	1
cellular response to histamine	1
signal transduction	1
phospholipase C-activating serotonin receptor signaling pathway	1

Indications & clinical

Indications

5 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
seasonal allergic rhinitis	4	MONDO:0005324	EFO:0003956
allergic rhinitis	4	MONDO:0011786	EFO:0005854
perennial allergic rhinitis	4	MONDO:0024332	EFO:1001417
urticaria	4	MONDO:0005492	EFO:0005531
allergic disease	4	MONDO:0005271	MONDO:0005271

8 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
asthma	3	MONDO:0004979	MONDO:0004979
eosinophilic esophagitis	2	MONDO:0005361	EFO:0004232
breast neoplasm	2	MONDO:0021100	MONDO:0007254
lymphangioleiomyomatosis	2	MONDO:0011705	MONDO:0011705
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
atopic eczema	1	MONDO:0004980	EFO:0000274
rheumatoid arthritis	1	MONDO:0008383	EFO:0000685
multiple sclerosis	1	MONDO:0005301	MONDO:0005301

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 58.

Phase distribution

Phase	Trials
PHASE4	15
PHASE3	13
PHASE2	13
Not specified	7
PHASE1	6
EARLY_PHASE1	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07101445	PHASE4	RECRUITING	Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
NCT07532993	PHASE4	NOT_YET_RECRUITING	Comparison of Antihistamine and Antileukotriene Add-On Therapy to Intranasal Corticosteroid in Allergic Rhinitis
NCT00561717	PHASE4	COMPLETED	A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
NCT00730912	PHASE4	COMPLETED	Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)
NCT00963573	PHASE4	COMPLETED	Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)
NCT01451996	PHASE4	COMPLETED	The Efficacy of Claritin in Healthy Subjects
NCT01469234	PHASE4	COMPLETED	A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)
NCT02513290	PHASE4	COMPLETED	Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine
NCT02932774	PHASE4	COMPLETED	Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
NCT03004131	PHASE4	COMPLETED	MP-AzeFlu Allergen Chamber - Onset of Action Study
NCT05265910	PHASE4	COMPLETED	A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
NCT05750875	PHASE4	COMPLETED	Gabapentin Versus Loratadine in Uremic Pruritus
NCT06019728	PHASE4	COMPLETED	A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
NCT06217367	PHASE4	UNKNOWN	Over-the-Counter Antihistamines & Heat Stress
NCT06250400	PHASE4	UNKNOWN	Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)
NCT06531707	PHASE3	RECRUITING	Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine
NCT00423995	PHASE3	COMPLETED	Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)
NCT00960141	PHASE3	COMPLETED	A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
NCT00963469	PHASE3	COMPLETED	Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)
NCT00963599	PHASE3	COMPLETED	Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
NCT00972738	PHASE3	COMPLETED	Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
NCT00979901	PHASE3	COMPLETED	Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)
NCT01055756	PHASE3	WITHDRAWN	Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis
NCT01413958	PHASE3	COMPLETED	Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)
NCT02007434	PHASE3	COMPLETED	Patient Experience Study of Deoxycholic Acid Injection
NCT02478398	PHASE3	COMPLETED	Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
NCT03855228	PHASE3	COMPLETED	Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
NCT05043350	PHASE2/PHASE3	COMPLETED	Combined Antihistaminics Therapy in COVID 19 Patients
NCT05243706	PHASE3	UNKNOWN	Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy
NCT05421416	PHASE2	RECRUITING	Loratadine for the Prevention of G-CSF-related Bone Pain
NCT00481676	PHASE2	COMPLETED	Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
NCT01311336	PHASE2	UNKNOWN	Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain
NCT01330017	PHASE2	COMPLETED	Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)
NCT01712009	PHASE2	COMPLETED	NOLAN: Naproxen or Loratadine and Neulasta
NCT02339714	PHASE2	COMPLETED	Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis
NCT02495077	PHASE2	COMPLETED	Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
NCT02576808	PHASE2	COMPLETED	Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis
NCT03376594	PHASE2	COMPLETED	Benjakul Extract and Loratadine for Treatment Allergic Rhinitis Patients
NCT03640273	PHASE2	COMPLETED	Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
NCT03883386	PHASE2	TERMINATED	Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
NCT04248712	PHASE2	TERMINATED	Antihistamines in Eosinophilic Esophagitis
NCT05190627	PHASE2	UNKNOWN	Effect of Loratadine in Lymphangioleiomyomatosis
NCT06265077	PHASE1/PHASE2	COMPLETED	Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients
NCT01390441	PHASE1	TERMINATED	A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
NCT02583594	PHASE1	COMPLETED	A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
NCT02593747	PHASE1	COMPLETED	To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup
NCT03517930	PHASE1	COMPLETED	A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
NCT03517943	PHASE1	COMPLETED	A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects
NCT06955741	PHASE1	COMPLETED	A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants
NCT04211259	EARLY_PHASE1	RECRUITING	Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
NCT02392039	EARLY_PHASE1	TERMINATED	Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma
NCT07300735	Not specified	RECRUITING	Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
NCT07575464	Not specified	NOT_YET_RECRUITING	Efficacy of Auricular Acupressure Combined With Antihistamines in Patients With Wind-Heat Type Urticaria.
NCT00762983	Not specified	COMPLETED	Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)
NCT00845546	Not specified	COMPLETED	Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions
NCT02305979	Not specified	COMPLETED	Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
NCT02653339	Not specified	UNKNOWN	Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.
NCT07380178	Not specified	COMPLETED	The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

300 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1, SLC6A15
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	HRH1
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HRH1
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	HRH1
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	HRH1
ABEMACICLIB	ChEMBL	Phase 4 (approved)	HRH1
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	HRH1
ACRIVASTINE	ChEMBL	Phase 4 (approved)	HRH1
AMIODARONE	ChEMBL	Phase 4 (approved)	HRH1
AMISULPRIDE	ChEMBL	Phase 4 (approved)	HRH1
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	HRH1
AMOXAPINE	ChEMBL	Phase 4 (approved)	HRH1
AMSACRINE	ChEMBL	Phase 4 (approved)	HRH1
ANTAZOLINE	ChEMBL	Phase 4 (approved)	HRH1
APOMORPHINE	ChEMBL	Phase 4 (approved)	HRH1
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HRH1
ASENAPINE	ChEMBL	Phase 4 (approved)	HRH1
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	HRH1
ATOMOXETINE	ChEMBL	Phase 4 (approved)	HRH1
AZATADINE	ChEMBL	Phase 4 (approved)	HRH1
AZELASTINE	ChEMBL	Phase 4 (approved)	HRH1
BENFLUOREX	ChEMBL	Phase 4 (approved)	HRH1
BENPERIDOL	ChEMBL	Phase 4 (approved)	HRH1
BENZBROMARONE	ChEMBL	Phase 4 (approved)	HRH1
BENZTROPINE	ChEMBL	Phase 4 (approved)	HRH1
BEPRIDIL	ChEMBL	Phase 4 (approved)	HRH1
BETAMETHASONE PHOSPHORIC ACID	ChEMBL	Phase 4 (approved)	HRH1
BIPERIDEN	ChEMBL	Phase 4 (approved)	HRH1
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	HRH1
BROMPERIDOL	ChEMBL	Phase 4 (approved)	HRH1
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	HRH1
BUCLIZINE	ChEMBL	Phase 4 (approved)	HRH1
BUPROPION	ChEMBL	Phase 4 (approved)	HRH1
BUSPIRONE	ChEMBL	Phase 4 (approved)	HRH1
BUTRIPTYLINE	ChEMBL	Phase 4 (approved)	HRH1
CABERGOLINE	ChEMBL	Phase 4 (approved)	HRH1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	HRH1
CAPTOPRIL	ChEMBL	Phase 4 (approved)	HRH1
CARBINOXAMINE	ChEMBL	Phase 4 (approved)	HRH1
CARIPRAZINE	ChEMBL	Phase 4 (approved)	HRH1
CETIRIZINE	ChEMBL	Phase 4 (approved)	HRH1
CHLORDIAZEPOXIDE	ChEMBL	Phase 4 (approved)	HRH1
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	HRH1
CHLORPHENTERMINE	ChEMBL	Phase 4 (approved)	HRH1
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	HRH1
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	HRH1
CINACALCET	ChEMBL	Phase 4 (approved)	HRH1
CINNARIZINE	ChEMBL	Phase 4 (approved)	HRH1
CISAPRIDE	ChEMBL	Phase 4 (approved)	HRH1
CITALOPRAM	ChEMBL	Phase 4 (approved)	HRH1
CLEMASTINE	ChEMBL	Phase 4 (approved)	HRH1
CLOFAZIMINE	ChEMBL	Phase 4 (approved)	HRH1
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	HRH1
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	HRH1
CLOZAPINE	ChEMBL	Phase 4 (approved)	HRH1
CYCLIZINE	ChEMBL	Phase 4 (approved)	HRH1
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	HRH1
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	HRH1
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	HRH1
DESIPRAMINE	ChEMBL	Phase 4 (approved)	HRH1
DEXBROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	HRH1
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	HRH1
DIBENZEPIN	ChEMBL	Phase 4 (approved)	HRH1
DICYCLOMINE	ChEMBL	Phase 4 (approved)	HRH1
DIETHYLPROPION	ChEMBL	Phase 4 (approved)	HRH1
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	HRH1
DIPHEMANIL	ChEMBL	Phase 4 (approved)	HRH1
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	HRH1
DOMPERIDONE	ChEMBL	Phase 4 (approved)	HRH1
DOTHIEPIN	ChEMBL	Phase 4 (approved)	HRH1
DOXEPIN	ChEMBL	Phase 4 (approved)	HRH1
DROPERIDOL	ChEMBL	Phase 4 (approved)	HRH1
DULOXETINE	ChEMBL	Phase 4 (approved)	HRH1
DYCLONINE	ChEMBL	Phase 4 (approved)	HRH1
EBASTINE	ChEMBL	Phase 4 (approved)	HRH1
EPALRESTAT	ChEMBL	Phase 4 (approved)	HRH1
ESCITALOPRAM	ChEMBL	Phase 4 (approved)	HRH1
FENTANYL	ChEMBL	Phase 4 (approved)	HRH1
FEXOFENADINE	ChEMBL	Phase 4 (approved)	HRH1
FLUDROCORTISONE	ChEMBL	Phase 4 (approved)	HRH1
FLUOXETINE	ChEMBL	Phase 4 (approved)	HRH1
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HRH1
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	HRH1
GLYCOPYRRONIUM BROMIDE	ChEMBL	Phase 4 (approved)	HRH1
HALOPERIDOL	ChEMBL	Phase 4 (approved)	HRH1
HISTAMINE	ChEMBL	Phase 4 (approved)	HRH1
HYDROXOCOBALAMIN	ChEMBL	Phase 4 (approved)	HRH1
HYDROXYZINE	ChEMBL	Phase 4 (approved)	HRH1
IDARUBICIN	ChEMBL	Phase 4 (approved)	HRH1
ILOPERIDONE	ChEMBL	Phase 4 (approved)	HRH1
IMIPRAMINE	ChEMBL	Phase 4 (approved)	HRH1
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	HRH1
IPRINDOLE	ChEMBL	Phase 4 (approved)	HRH1
KETANSERIN	ChEMBL	Phase 4 (approved)	HRH1
KETOTIFEN	ChEMBL	Phase 4 (approved)	HRH1
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	HRH1
LEVOCETIRIZINE	ChEMBL	Phase 4 (approved)	HRH1
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	HRH1
LORCASERIN	ChEMBL	Phase 4 (approved)	HRH1
LOXAPINE	ChEMBL	Phase 4 (approved)	HRH1